NIH Guide: Weekly Index for June 4, 2021

Funding Opportunities

• Shared Personal Protective Equipment (PPE) Resources (S10 Clinical Trial Not Allowed)
  (PAR-21-257)
  Office of the Director, NIH
  National Institute of Allergy and Infectious Diseases
  Application Receipt Date(s): Multiple dates, see announcement.
• Limited Competition for the Continuation of the National Consortium on Alcohol and Neurodevelopment in Adolescence (NCANDA) Research Project Sites (U01 Clinical Trials Optional)
  (RFA-AA-21-007)
  National Institute on Alcohol Abuse and Alcoholism
  National Institute on Drug Abuse
  Application Receipt Date(s): Not Applicable
• Limited Competition for the Continuation of the National Consortium on Alcohol and Neurodevelopment in Adolescence (NCANDA) Administrative Resource (U24 Clinical Trials Optional)
  (RFA-AA-21-008)
  National Institute on Alcohol Abuse and Alcoholism
  National Institute on Drug Abuse
  Application Receipt Date(s): Not Applicable
• Limited Competition for the Continuation of the National Consortium on Alcohol and Neurodevelopment in Adolescence (NCANDA) Data Analysis Resource (U24 Clinical Trials Optional)
  (RFA-AA-21-009)
  National Institute on Alcohol Abuse and Alcoholism
  National Institute on Drug Abuse
  Application Receipt Date(s): Not Applicable
• Collaborative Initiative on Fetal Alcohol Spectrum Disorders (CIFASD), Research Project (U01 Clinical Trial optional)
  (RFA-AA-21-010)
  National Institute on Alcohol Abuse and Alcoholism
  Application Receipt Date(s): August 16, 2021
• Collaborative Initiative on Fetal Alcohol Spectrum Disorders (CIFASD), Administrative Resource (U24) (Clinical Trial Not Allowed)
  (RFA-AA-21-011)
  National Institute on Alcohol Abuse and Alcoholism
  Application Receipt Date(s): August 16, 2021
• Collaborative Initiative on Fetal Alcohol Spectrum Disorders (CIFASD), Diagnostic-Telemedicine Resource (U24 Clinical Trial Not Allowed)
  (RFA-AA-21-012)
  National Institute on Alcohol Abuse and Alcoholism
  Application Receipt Date(s): August 16, 2021
• Collaborative Initiative on Fetal Alcohol Spectrum Disorders (CIFASD), Data Coordination Resource (U24 Clinical Trial Not Allowed)
  (RFA-AA-21-013)
  National Institute on Alcohol Abuse and Alcoholism
  Application Receipt Date(s): August 16, 2021
• Collaborative Initiative on Fetal Alcohol Spectrum Disorders (CIFASD), Developmental Project (UH2 Clinical Trial Optional)
  (RFA-AA-21-014)
  National Institute on Alcohol Abuse and Alcoholism
  Application Receipt Date(s): August 16, 2021
• The Early Detection Research Network: Clinical Validation Centers (U01 Clinical Trial Optional)
  (RFA-CA-21-033)
  National Cancer Institute
  Application Receipt Date(s): September 9, 2021 All applications are due by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on the listed date(s) Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.
• The Early Detection Research Network: Data Management and Coordinating Center (U24 Clinical Trial Not Allowed)
  (RFA-CA-21-034)
  National Cancer Institute
  Application Receipt Date(s): September 9, 2021 All applications are due by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on the listed date(s) Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.
• The Early Detection Research Network: Biomarker Characterization Centers (U2C Clinical Trial Not Allowed)
  (RFA-CA-21-035)
  National Cancer Institute
  National Institute of Dental and Craniofacial Research
  Application Receipt Date(s): September 9, 2021 All applications are due by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on the listed date(s). No late applications will be accepted for this FOA.
• Exploratory Studies to Investigate the Mechanisms of Interrelationship Between Sleep and Substance Use Disorders (R61/R33 Clinical Trials Not Allowed)
  (RFA-DA-22-016)
  National Institute on Drug Abuse
  Application Receipt Date(s): October 14, 2021
• Characterization of Islet-derived Extracellular Vesicles for Improved Detection, Monitoring, Classification, and Treatment of Type 1 Diabetes (R01 Clinical Trial Not Allowed)
  (RFA-DK-21-016)
  National Institute of Diabetes and Digestive and Kidney Diseases
  Application Receipt Date(s): November 03, 2021
• Non-Human Primate Developmental Genotype-Tissue Expression (NHP dGTEx) Project (U24 Clinical Trials Not Allowed)
  (RFA-HG-21-026)
  National Human Genome Research Institute
  National Institute of Mental Health
  Division of Program Coordination, Planning and Strategic Initiatives, Office of Research Infrastructure Programs
  Application Receipt Date(s): August 2, 2021 All applications are due by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on the listed date(s) Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.
• NIH Directors Transformative Research Awards (R01 Clinical Trial Optional)
  (RFA-RM-21-017)
  Office of Strategic Coordination (Common Fund)
  Application Receipt Date(s): September 01, 2021